Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

NCT05951179 is registered in ClinicalTrials.gov with Protara Therapeutics as lead sponsor.

NCT NCT05951179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05951179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer
Lead sponsor
Protara Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
September 15, 2023
Completion date
March 31, 2032
Enrollment
131 (estimated)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer